German biotech firm MorphoSys (FSE: MOR) and Zurich, Switzerland-based start-up G7 Therapeutics have entered into an agreement to collaborate on novel antibody therapeutics that target G protein-coupled receptors (GPCRs) and potentially other disease-related transmembrane proteins, such as ion channels.
Under the terms of the accord, G7 Therapeutics will generate a set of disease-relevant receptors proposed by MorphoSys. MorphoSys will then apply its proprietary Ylanthia antibody library to discover and develop antibody therapeutics against these receptors. MorphoSys has the right to sub-license third parties with access to these targets in conjunction with therapeutic antibody candidates. No financial terms of the deal were disclosed.
Promising addition to pipeline
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze